Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07677059 · ClinicalTrials.gov registry record · Phase 2
A Long-term Study of KT-621 Administered Orally to Participants With Asthma Previously Enrolled in a KT-621 Asthma Study
A Phase 2 study, sponsored by Kymera Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 264
- Enrollment target
NCT07677059: Recruiting Phase 2 study, sponsored by Kymera Therapeutics.
NCT07677059 is a Phase 2 study that is actively recruiting participants, run by Kymera Therapeutics. The registered enrollment target is 264 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07677059, a Phase 2 study, is actively recruiting participants, sponsored by Kymera Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 264 participants
- Enrollment target
Study Summary
This Phase 2b open-label, long-term extension study is designed to evaluate the long-term safety and efficacy of KT-621 in participants with asthma who were previously enrolled in the parent study (KT621-AS-202) of KT-621 for asthma. The main goals of this study are to investigate the long-term safety and tolerability of KT-621, the long-term efficacy of KT-621 at treating asthma, and how KT-621 behaves in the body long-term.
Interventions
- DRUG KT-621
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 264 participants |
| Start Date | 2026-07 |
| Est. Completion | 2028-12 |
| Phase | Phase 2 |
What NCT07677059 shows while recruiting
NCT07677059 is an interventional study that assigns participants to a tested intervention. The registered 264 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% higher).
The record links to 0 conditions, and to 1 intervention - of which KT-621 is the first listed.
NCT07677059 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07677059 about?
NCT07677059 is a clinical study titled "A Long-term Study of KT-621 Administered Orally to Participants With Asthma Previously Enrolled in a KT-621 Asthma Study". This Phase 2b open-label, long-term extension study is designed to evaluate the long-term safety and efficacy of KT-621 in participants with asthma who were previously enrolled in the parent study (KT621-AS-202) of KT-621 for asthma. The main goals of this study are to investigate the long-term safe...
What is the current status of trial NCT07677059?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 264 participants. The study started on 2026-07. Estimated completion is 2028-12.
What interventions are being tested in trial NCT07677059?
The interventions under investigation include: KT-621 (DRUG).
Who is sponsoring clinical trial NCT07677059?
This trial is sponsored by Kymera Therapeutics, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07677059's enrollment target sits among peer trials
264 210th of 2000 higher than 1,791 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04101669 · 264 participants · NA
RESET System Pivotal Trial (Rev F)
- NCT04295863 · 264 participants · Phase 1
Comparing Dosing Intervals of Nivolumab or Pembrolizumab in Locally Advanced or Metastatic Cancers
- NCT05220202 · 264 participants · NA
MOTIVATE to Improve Outcomes for Older Veterans With Musculoskeletal Pain and Depression
- NCT05473013 · 264 participants · NA
Optimizing Digital Health Technology Interventions to Increase Skill Acquisition and Utilization
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia